BCM
CRBU icon

Bayesian Capital Management’s Caribou Biosciences CRBU Stock Holding History

Bayesian Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-26,084
Closed -$51.1K – 736
2024
Q3 		$51.1K Buy
+26,084
New +$53.4K 0.01% 625
2024
Q2 		– Sell
-29,284
Closed -$151K – 807
2024
Q1 		$151K Buy
+29,284
New +$181K 0.01% 683
2023
Q1 		– Sell
-13,900
Closed -$87.3K – 844
2022
Q4 		$87.3K Buy
+13,900
New +$124K 0.01% 672

Other funds holding CRBU

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bayesian Capital Management's CRBU Position: Q4 2024 in Review

Bayesian Capital Management sold out of Caribou Biosciences (CRBU) in Q4 2024, closing a stake of 26,084 shares — an estimated $51.1K sold.

Bayesian Capital Management first reported a position in CRBU in Q4 2022 and held it in 3 quarters. The position peaked at $151K in Q1 2024. 133 funds tracked by Wall St. Rank hold CRBU as of Q4 2024.

  • Bayesian Capital Management reported no remaining Caribou Biosciences position as of Q4 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 26,084 Caribou Biosciences shares in Q4 2024, an estimated $51.1K.
  • Bayesian Capital Management first reported a position in Caribou Biosciences in Q4 2022 and held it in 3 quarters.
  • Bayesian Capital Management's Caribou Biosciences position peaked at $151K in Q1 2024.
  • 133 funds tracked by Wall St. Rank held Caribou Biosciences as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.